Peter Kaiser, MD
Ophthalmology · Cleveland, OHNPI 1558300590
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $942,128 of the $1,499,428 with a category attached, or 62.8%. 45 manufacturers reported payments, led by Ocular Therapeutix, Inc. at 31.5% of the total. Reporting peaked in 2022 at $555,376 and has fallen 97.5% since, to $14,127 in 2025. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 402 payments — averaging $3729.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$473K
- Astellas Pharma US Inc$233K
- AbbVie$180K
- Novartis$159K
- Novartis Pharma AG$76K
- Regeneron$74K
- plus $304K from 39 others
Across 22 payments — averaging $3627.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$42K
- Novartis Pharma AG$34K
- Regeneron$4K
What the payments were for
- Consulting fees$942,12863%
- Speaking & faculty fees$57,0674%
- Travel & lodging$17,7481%
- Food & beverage$10,7651%
- Ownership interest$471,72031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$239,050
- BEOVU$170,471
- EYLEA$66,137
- OZURDEX$43,973
- EYLEA HD$30,813
- BLZ_BEOVU_OPHTHALMOLOGY$22,576
- RTH258A_BEOVU_OPHTHALMOLOGY$19,603
- TAKHZYRO$16,000
- Cimerli$11,000
- SUSVIMO$7,966
- CIRRUS HD-OCT$5,500
- CLARUS$5,500
- FORUM$5,500
- Jetrea$5,500
- LUMAKRAS$3,932
- VISUDYNE$3,106
- YUTIQ$3,000
- E301$2,400
- Prokera$1,500
- AmnioGraft$1,500
How this compares
$1,499,428 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 12 | $983 |
| Ketorolac Tromethamine | 18 | $923 |
| Prednisolone Acetate | 15 | $754 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $163 |
| Latanoprost | 14 | $133 |
| Brimonidine Tartrate | 19 | $65 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Cleveland
- Justis EhlersCleveland$639K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
- Yasha ModiCleveland$234K
- Faruk OrgeCleveland$158K
- Danny MammoCleveland$149K
- Douglas RheeCleveland$138K
- Jeffrey GosheCleveland$82K
- William DuppsCleveland$44K
- Shree KurupCleveland$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.